http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2443738-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_754f2477f246d85d1b1931c01835c862 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2007-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2220c866e06bc873fec4cb92f60ffb54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66a80c0839cd38d409768a80e9d4d955 |
| publicationDate | 2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2443738-A |
| titleOfInvention | A sustained release methotrexate composition and methods of use thereof |
| abstract | Described herein is an oral pharmaceutical composition comprising methotrexate which has a sustained release profile. Measured by the USP type II dissolution apparatus (paddle method) the composition exhibits a release profile with more than about 80 % of the methotrexate released within 8-18 hours, see the dissolution profiles of formulation P2, P4, P5, and P6 at figure 6. Further the composition comprises a hydrophilic polymer as for example Carbopol and gas generating agents in form of carbonate salt or bicarbonate salt. Consequently, the composition will swell and float in the stomach, which delays the passage of the composition through the pylorus and increases gastrointestinal residence. In addition methods of treating or preventing diseases as for example autoimmune diseases and cancer by treatment with the oral sustained release methotrexate composition are described. In some embodiments, these approaches improve the pharmacotherapeutic performance of methotrexate therapy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9770414-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10028911-B2 |
| priorityDate | 2006-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 871.